CA3236328A1 - Methods of treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism - Google Patents
Methods of treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism Download PDFInfo
- Publication number
- CA3236328A1 CA3236328A1 CA3236328A CA3236328A CA3236328A1 CA 3236328 A1 CA3236328 A1 CA 3236328A1 CA 3236328 A CA3236328 A CA 3236328A CA 3236328 A CA3236328 A CA 3236328A CA 3236328 A1 CA3236328 A1 CA 3236328A1
- Authority
- CA
- Canada
- Prior art keywords
- dose
- imb
- subjects
- compound
- trimetazidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163274389P | 2021-11-01 | 2021-11-01 | |
| US63/274,389 | 2021-11-01 | ||
| PCT/US2022/048401 WO2023076665A1 (en) | 2021-11-01 | 2022-10-31 | Methods for treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3236328A1 true CA3236328A1 (en) | 2023-05-04 |
Family
ID=86158627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3236328A Pending CA3236328A1 (en) | 2021-11-01 | 2022-10-31 | Methods of treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250235447A1 (https=) |
| EP (1) | EP4426301A4 (https=) |
| JP (1) | JP2024540172A (https=) |
| KR (1) | KR20240095326A (https=) |
| CN (1) | CN118647381A (https=) |
| AU (1) | AU2022376557A1 (https=) |
| CA (1) | CA3236328A1 (https=) |
| IL (1) | IL312523A (https=) |
| WO (1) | WO2023076665A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025054580A1 (en) * | 2023-09-08 | 2025-03-13 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Compositions and methods for increasing myocardial capillary formation, reducing left ventricular hypertrophy and/or reducing ventricular dysfunction |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL283725B2 (en) * | 2017-06-20 | 2024-04-01 | Imbria Pharmaceuticals Inc | Compositions and methods for increasing efficiency of cardiac metabolism |
| TWI683808B (zh) * | 2017-07-18 | 2020-02-01 | 德商菲尼克斯 Ｆｘｒ有限責任公司 | 含有胺或(硫)醯胺之lxr調節劑 |
| EP3976103A4 (en) * | 2019-05-31 | 2023-06-28 | Imbria Pharmaceuticals, Inc. | Methods of altering cardiac remodeling using compounds that promote glucose oxidation |
-
2022
- 2022-10-31 US US18/703,512 patent/US20250235447A1/en active Pending
- 2022-10-31 CN CN202280085857.0A patent/CN118647381A/zh active Pending
- 2022-10-31 AU AU2022376557A patent/AU2022376557A1/en active Pending
- 2022-10-31 KR KR1020247018009A patent/KR20240095326A/ko active Pending
- 2022-10-31 WO PCT/US2022/048401 patent/WO2023076665A1/en not_active Ceased
- 2022-10-31 IL IL312523A patent/IL312523A/en unknown
- 2022-10-31 EP EP22888285.8A patent/EP4426301A4/en active Pending
- 2022-10-31 JP JP2024525619A patent/JP2024540172A/ja active Pending
- 2022-10-31 CA CA3236328A patent/CA3236328A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250235447A1 (en) | 2025-07-24 |
| WO2023076665A1 (en) | 2023-05-04 |
| EP4426301A1 (en) | 2024-09-11 |
| JP2024540172A (ja) | 2024-10-31 |
| AU2022376557A1 (en) | 2024-05-02 |
| CN118647381A (zh) | 2024-09-13 |
| KR20240095326A (ko) | 2024-06-25 |
| IL312523A (en) | 2024-07-01 |
| EP4426301A4 (en) | 2025-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sadat et al. | Does ascorbic acid protect against contrast-induced acute kidney injury in patients undergoing coronary angiography: a systematic review with meta-analysis of randomized, controlled trials | |
| US20250221986A1 (en) | Methods of treating kidney conditions using modified forms of trimetazidine | |
| US20230210845A1 (en) | Dosing methods for treatment of cardiovascular conditions | |
| Karamat et al. | The acute effect of beta‐guanidinopropionic acid versus creatine or placebo in healthy men (ABC‐Trial): a randomized controlled first‐in‐human trial | |
| US20250235447A1 (en) | Methods for treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism | |
| Baranowski et al. | Effect of exogenous β-hydroxybutyrate on BDNF signaling, cognition, and amyloid precursor protein processing in humans with T2D and insulin-resistant rodents | |
| US20210401833A1 (en) | Modified release formulations of modified forms of trimetazidine | |
| EP4171232A1 (en) | Modified release formulations of modified forms of trimetazidine | |
| Dwivedi et al. | Beta-thalassemia, hyperlipoproteinemia (a), and metabolic syndrome: its low-cost holistic therapy | |
| US20210401834A1 (en) | Modified release formulations of modified forms of trimetazidine | |
| Tablets et al. | PrJAMP Pioglitazone | |
| Agent | Pr PRO-PIOGLITAZONE | |
| Tablets et al. | Pr ACT PIOGLITAZONE | |
| Extremera et al. | Clinical Trials on Diabetes Mellitus | |
| Agent | Pr AURO-PIOGLITAZONE | |
| Agent | PrRAN™-PIOGLITAZONE | |
| Agent | PrACH-Pioglitazone | |
| Agent | PrMYLAN-METFORMIN | |
| Agent | KOMBOGLYZE® | |
| Standard et al. | PrACCEL PIOGLITAZONE | |
| Agent | PrVAN-Pioglitazone | |
| Hydrochloride et al. | PrMYLAN-PIOGLITAZONE | |
| Tablets et al. | RAN-Pioglitazone | |
| Agent | PrJamp-Pioglitazone | |
| Agent | PrSANDOZ PIOGLITAZONE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241025 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241025 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241025 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251024 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251024 |